A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England

Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsada, Ahmed, Zalin‐Miller, Amy, Knott, Craig, Caravotas, Leonidas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175886/
https://www.ncbi.nlm.nih.gov/pubmed/35844690
http://dx.doi.org/10.1002/jha2.214
_version_ 1784722543909797888
author Elsada, Ahmed
Zalin‐Miller, Amy
Knott, Craig
Caravotas, Leonidas
author_facet Elsada, Ahmed
Zalin‐Miller, Amy
Knott, Craig
Caravotas, Leonidas
author_sort Elsada, Ahmed
collection PubMed
description Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow‐up time of 6.4 months from T (0), median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real‐world data provide useful clinical insight into a little‐studied patient population and highlight the poor outcomes in the UK setting.
format Online
Article
Text
id pubmed-9175886
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91758862022-07-14 A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England Elsada, Ahmed Zalin‐Miller, Amy Knott, Craig Caravotas, Leonidas EJHaem Short Reports Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow‐up time of 6.4 months from T (0), median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real‐world data provide useful clinical insight into a little‐studied patient population and highlight the poor outcomes in the UK setting. John Wiley and Sons Inc. 2021-06-10 /pmc/articles/PMC9175886/ /pubmed/35844690 http://dx.doi.org/10.1002/jha2.214 Text en © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Elsada, Ahmed
Zalin‐Miller, Amy
Knott, Craig
Caravotas, Leonidas
A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
title A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
title_full A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
title_fullStr A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
title_full_unstemmed A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
title_short A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
title_sort registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and cd38‐targeted monoclonal antibody therapy in england
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175886/
https://www.ncbi.nlm.nih.gov/pubmed/35844690
http://dx.doi.org/10.1002/jha2.214
work_keys_str_mv AT elsadaahmed aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT zalinmilleramy aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT knottcraig aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT caravotasleonidas aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT elsadaahmed registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT zalinmilleramy registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT knottcraig registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland
AT caravotasleonidas registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland

Ejemplares similares